21757018|t|Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
21757018|a|The 5-hydroxytryptamine(6) (5-HT(6)) receptor has been suggested to play an important role in the regulation of memory and cognition. In the present study, our aim was to investigate whether the novel, selective 5-HT(6) antagonists compound (CMP) X and CMP Y and the reference 5-HT(6) antagonist GSK-742457 could ameliorate impairments in episodic memory in 3-months-old male Wistar rats. The acetylcholinesterase inhibitor (AChEI) donepezil (Aricept , approved for symptomatic treatment of Alzheimer's disease, AD) was used as a positive reference compound. First, effects of the 5-HT(6) antagonists CMP X, CMP Y and GSK-742457 were investigated on object recognition task (ORT) performance in rats treated with the muscarinic antagonist scopolamine (0.1mg/kg, administered intraperitoneally, i.p., 30 min before trial 1). Second, effects of the combination of suboptimal doses of 5-HT(6) antagonists CMP X and CMP Y with the AChEI donepezil were studied, to determine whether the 5-HT(6) antagonists show additive synergism with donepezil in the ORT. Finally, effects of CMP Y, GSK-742457 and donepezil were investigated on object location task (OLT) performance in rats treated with scopolamine. Donepezil (1mg/kg, oral administration, p.o.), GSK-742457 (3mg/kg, i.p.), CMP X (3mg/kg, i.p.) and CMP Y (30 mg/kg, p.o.), all ameliorated the scopolamine-induced deficits in object recognition. In the ORT, we have found that combined administration of subthreshold doses of CMP X (1mg/kg, i.p.) and CMP Y (10mg/kg, p.o.) with the AChEI donepezil (0.1mg/kg, p.o.), enhanced memory performance in Wistar rats with deficits induced by scopolamine. Donepezil (0.1mg/kg, p.o.) alone had no discernable effects on performance. This suggests additive synergistic effects of the 5-HT(6) antagonists (CMP X and CMP Y) with donepezil on cognitive impairment. Finally, donepezil (1mg/kg, p.o.), GSK-742457 (10mg/kg, p.o.) and CMP Y (30 mg/kg, p.o.) also reduced scopolamine-induced deficits in the OLT. In conclusion, the 5-HT(6) antagonists were found to clearly improve episodic memory deficits induced by scopolamine. In addition, co-administration of the 5-HT(6) receptor antagonists CMP X and CMP Y with the AChEI donepezil to cognitively impaired rats also resulted in potentially additive enhancing effects on cognition. This suggests that these compounds could have potential as monotherapy, but also as adjunctive therapy in patients with AD treated with common treatments such as donepezil.
21757018	48	59	scopolamine	Chemical	MESH:D012601
21757018	68	83	memory deficits	Disease	MESH:D008569
21757018	146	150	rats	Species	10116
21757018	364	383	5-HT(6) antagonists	Chemical	-
21757018	393	400	(CMP) X	Chemical	-
21757018	405	410	CMP Y	Chemical	-
21757018	448	458	GSK-742457	Chemical	MESH:C548140
21757018	476	506	impairments in episodic memory	Disease	MESH:D008569
21757018	535	539	rats	Species	10116
21757018	545	565	acetylcholinesterase	Gene	83817
21757018	584	593	donepezil	Chemical	MESH:D000077265
21757018	595	602	Aricept	Chemical	MESH:D000077265
21757018	643	662	Alzheimer's disease	Disease	MESH:D000544
21757018	664	666	AD	Disease	MESH:D000544
21757018	733	752	5-HT(6) antagonists	Chemical	-
21757018	753	758	CMP X	Chemical	-
21757018	760	765	CMP Y	Chemical	-
21757018	770	780	GSK-742457	Chemical	MESH:C548140
21757018	847	851	rats	Species	10116
21757018	891	902	scopolamine	Chemical	MESH:D012601
21757018	1034	1053	5-HT(6) antagonists	Chemical	-
21757018	1054	1059	CMP X	Chemical	-
21757018	1064	1069	CMP Y	Chemical	-
21757018	1085	1094	donepezil	Chemical	MESH:D000077265
21757018	1134	1153	5-HT(6) antagonists	Chemical	-
21757018	1183	1192	donepezil	Chemical	MESH:D000077265
21757018	1225	1230	CMP Y	Chemical	-
21757018	1232	1242	GSK-742457	Chemical	MESH:C548140
21757018	1247	1256	donepezil	Chemical	MESH:D000077265
21757018	1320	1324	rats	Species	10116
21757018	1338	1349	scopolamine	Chemical	MESH:D012601
21757018	1351	1360	Donepezil	Chemical	MESH:D000077265
21757018	1398	1408	GSK-742457	Chemical	MESH:C548140
21757018	1425	1430	CMP X	Chemical	-
21757018	1450	1455	CMP Y	Chemical	-
21757018	1494	1505	scopolamine	Chemical	MESH:D012601
21757018	1514	1544	deficits in object recognition	Disease	MESH:D020238
21757018	1626	1631	CMP X	Chemical	-
21757018	1651	1656	CMP Y	Chemical	-
21757018	1688	1697	donepezil	Chemical	MESH:D000077265
21757018	1754	1758	rats	Species	10116
21757018	1784	1795	scopolamine	Chemical	MESH:D012601
21757018	1797	1806	Donepezil	Chemical	MESH:D000077265
21757018	1923	1942	5-HT(6) antagonists	Chemical	-
21757018	1944	1949	CMP X	Chemical	-
21757018	1954	1959	CMP Y	Chemical	-
21757018	1966	1975	donepezil	Chemical	MESH:D000077265
21757018	1979	1999	cognitive impairment	Disease	MESH:D003072
21757018	2010	2019	donepezil	Chemical	MESH:D000077265
21757018	2036	2046	GSK-742457	Chemical	MESH:C548140
21757018	2067	2072	CMP Y	Chemical	-
21757018	2103	2114	scopolamine	Chemical	MESH:D012601
21757018	2163	2182	5-HT(6) antagonists	Chemical	-
21757018	2213	2237	episodic memory deficits	Disease	MESH:D008569
21757018	2249	2260	scopolamine	Chemical	MESH:D012601
21757018	2329	2334	CMP X	Chemical	-
21757018	2339	2344	CMP Y	Chemical	-
21757018	2360	2369	donepezil	Chemical	MESH:D000077265
21757018	2373	2393	cognitively impaired	Disease	MESH:D003072
21757018	2394	2398	rats	Species	10116
21757018	2575	2583	patients	Species	9606
21757018	2589	2591	AD	Disease	MESH:D000544
21757018	2631	2640	donepezil	Chemical	MESH:D000077265
21757018	Positive_Correlation	MESH:D012601	MESH:D020238
21757018	Negative_Correlation	MESH:D000077265	MESH:D020238
21757018	Negative_Correlation	MESH:D000077265	MESH:D000544
21757018	Negative_Correlation	MESH:C548140	MESH:D020238
21757018	Negative_Correlation	MESH:C548140	MESH:D008569
21757018	Negative_Correlation	MESH:D000077265	83817
21757018	Negative_Correlation	MESH:C548140	MESH:D012601
21757018	Positive_Correlation	MESH:D012601	MESH:D008569
21757018	Negative_Correlation	MESH:D000077265	MESH:D012601

